Denali Therapeutics Inc.

36.23-1.38-3.67%Vol 458.82K1Y Perf -27.39%
Aug 16th, 2022 16:00 DELAYED
BID30.00 ASK36.75
Open37.48 Previous Close37.61
Pre-Market- After-Market36.23
 - -  - -%
Target Price
67.91 
Analyst Rating
Strong Buy 1.38
Potential %
87.44 
Finscreener Ranking
★★+     47.41
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     51.17
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     49.96
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
43.74 
Earnings Rating
Strong Buy
Market Cap4.47B 
Earnings Date
10th Aug 2022
Alpha0.02 Standard Deviation0.21
Beta1.66 

Today's Price Range

35.8837.51

52W Range

20.2456.80

5 Year PE Ratio Range

-37.50136.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-5.97%
1 Month
4.41%
3 Months
44.23%
6 Months
8.34%
1 Year
-27.39%
3 Years
99.50%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DNLI36.23-1.3800-3.67
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
-
-258.50
-251.00
-
7.75
RevenueValueIndustryS&P 500US Markets
112.42M
0.91
-1.45
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.52-0.487.69
Q01 2022-0.47-0.53-12.77
Q04 2021-0.41-0.62-51.22
Q03 2021-0.51-0.69-35.29
Q02 2021-0.37-0.50-35.14
Q01 2021-0.37-0.58-56.76
Q04 2020-0.551.91447.27
Q03 20203.57-0.54-115.13
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.5123.88Positive
9/2022 QR-0.79-9.72Negative
12/2022 FY-2.66-2.31Negative
12/2023 FY-2.79-13.41Negative
Next Report Date-
Estimated EPS Next Report-0.51
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume458.82K
Shares Outstanding123.35K
Shares Float82.67M
Trades Count9.60K
Dollar Volume16.70M
Avg. Volume650.84K
Avg. Weekly Volume721.77K
Avg. Monthly Volume617.70K
Avg. Quarterly Volume613.06K

Denali Therapeutics Inc. (NASDAQ: DNLI) stock closed at 36.23 per share at the end of the most recent trading day (a -3.67% change compared to the prior day closing price) with a volume of 458.82K shares and market capitalization of 4.47B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 291 people. Denali Therapeutics Inc. CEO is Ryan J. Watts.

The one-year performance of Denali Therapeutics Inc. stock is -27.39%, while year-to-date (YTD) performance is -18.77%. DNLI stock has a five-year performance of %. Its 52-week range is between 20.24 and 56.8, which gives DNLI stock a 52-week price range ratio of 43.74%

Denali Therapeutics Inc. currently has a PE ratio of -16.40, a price-to-book (PB) ratio of 5.31, a price-to-sale (PS) ratio of 41.27, a price to cashflow ratio of 10.60, a PEG ratio of 2.32, a ROA of -20.26%, a ROC of -27.82% and a ROE of -29.01%. The company’s profit margin is 7.75%, its EBITDA margin is -251.00%, and its revenue ttm is $112.42 Million , which makes it $0.91 revenue per share.

Of the last four earnings reports from Denali Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.51 for the next earnings report. Denali Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Denali Therapeutics Inc. is Strong Buy (1.38), with a target price of $67.91, which is +87.44% compared to the current price. The earnings rating for Denali Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Denali Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Denali Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.54, ATR14 : 1.93, CCI20 : 82.89, Chaikin Money Flow : -0.02, MACD : 1.56, Money Flow Index : 51.68, ROC : 5.44, RSI : 54.29, STOCH (14,3) : 73.71, STOCH RSI : 0.54, UO : 61.03, Williams %R : -26.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Denali Therapeutics Inc. in the last 12-months were: Alexander O. Schuth (Option Excercise at a value of $12 301), Alexander O. Schuth (Sold 99 232 shares of value $4 831 679 ), Carole Ho (Sold 17 351 shares of value $770 918 ), Marc Tessier-Lavigne (Sold 92 431 shares of value $3 724 373 ), Ryan J. Watts (Option Excercise at a value of $399 984), Ryan J. Watts (Sold 74 592 shares of value $3 432 921 ), Steve E. Krognes (Option Excercise at a value of $42 500), Steve E. Krognes (Sold 16 732 shares of value $699 422 ), Vicki L. Sato (Sold 6 664 shares of value $346 474 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (75.00 %)
9 (75.00 %)
8 (72.73 %)
Moderate Buy
1 (8.33 %)
1 (8.33 %)
1 (9.09 %)
Hold
2 (16.67 %)
2 (16.67 %)
2 (18.18 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.38
Strong Buy
1.38
Strong Buy
1.41

Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

CEO: Ryan J. Watts

Telephone: +1 650 866-8548

Address: 161 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 291

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

58%42%

Bearish Bullish

58%42%

TipRanks News for DNLI

Thu, 06 Jan 2022 16:28 GMT Denali Therapeutics (DNLI) Receives a Buy from Morgan Stanley

- TipRanks. All rights reserved.

News

Stocktwits